Đánh giá kết quả điều trị ung thư phổi không tế bào nhỏ giai đoạn IV bằng Navelbin metronomic tại Bệnh viện Đại học Y Hà Nội

To evaluate the treatment results of Navelbine metronomic in stage IV non-small cell lung cancer (NSCLC). Patients and methods: Retrospective, descriptive study on30stage IV non-small cell lung cancer patients treated with Navelbin metronomic regimen at the Department of Oncology and Palliative Care, Hanoi Medical University Hospital from January 2014 to November 2020. Results: The mean age was67 years old, ratio male/female=6:1. All of the patients have performance status (PS) 2-3, in which PS3 accounted for 60%. Among 30 patients, 5 patients (16.7%) received first-line treatment, and 25 patients (83.3%) received second-line treatment. Most of the patients had underlying medical conditions, in which hypertension accounted for the highest rate (43.3%). The response rate was 36.7%, the PS was a statistically significant predictor of response (P<0.05). Median progression-free survival (PFS) was 8 months with first-line treatment and 6 months with second-line treatment (P>0.05). The rate of toxicity was low, mainly at a mild level (grade 1/2), the most common side effect was anemia with a rate of 30%, no patients had grade 3/4.Conclusion: Navelbine metronomic was safe and effective in stage IV NSCLC patients with poor performance status (PS 2-3) and comorbidities.